Alzamend Neuro, Inc. (ALZN) · Nov 18, 2026 · Other events
Exploratory fMRI data — n=6; no network-pair changes survived FDR correction
Alzamend Neuro’s presentation of AL001 fMRI data shows descriptive differences, but no network changes survived correction in a six-subject study.
Alzamend is a clinical-stage biotech trying to move AL001, its reformulated lithium candidate, through Phase II studies for Alzheimer’s disease, bipolar disorder, major depressive disorder and PTSD. The broader development story already included healthy-subject brain-imaging work and an ongoing bipolar-disorder study, so this presentation is an incremental scientific update rather than a new program milestone.
The data are descriptive, not confirmatory. Six healthy participants completed baseline and post-treatment imaging, but only four scans were available in each treatment condition; the study found inter-subject variability and descriptive differences between AL001 and lithium carbonate, with no network-pair changes surviving false-discovery-rate correction. 〔0〕 〔1〕
That leaves the core AL001 story largely unchanged. The imaging work may help characterize how the drug affects brain networks, but it does not establish clinical benefit, superiority over standard lithium, or a safety advantage. The very small sample and exploratory design make the findings hypothesis-generating rather than a meaningful advance in the development program. 〔2〕
Bottom line: This presentation adds scientific detail but does not materially advance or damage AL001’s clinical story. It confirms that the imaging signal remains preliminary and unproven at this sample size.
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!